Showing results (51-60 of 68) with videos related to
Sort By:
Pageof 7
Schizophrenia Bulletin Open|June 1, 2026
Impact of Healthcare Professional Role and Care Setting on Attitudes Toward Long-Acting Injectable Antipsychotics for Schizophrenia: A Subgroup Analysis of the Multinational ADVANCE StudyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.Drug Research|September 4, 2020
Single Ascending Dose Study to Assess Pharmacokinetic Linearity, Safety, and Tolerability of Trimetazidine - Modified Release in Healthy Human SubjectsThomas Körnicke, Deepa Arora, Abdus Samad, et al.Journal of Clinical Pharmacy and Therapeutics|January 20, 2019
A drug utilization study to evaluate effectiveness of risk minimization measures for trimetazidine in France, Hungary, Romania and SpainBirgit Ehlken, Massoud Toussi, Abdus Samad, et al.Contraception|October 2, 2021
Long-term safety of extended levonorgestrel-containing oral contraceptives in the United StatesSigal Kaplan, Monica L Bertoia, Florence T Wang, et al.Pharmacoepidemiology and Drug Safety|November 1, 2018
Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countriesDorothea von Bredow, Massoud Toussi, Abdus Samad, et al.Current Medical Research and Opinion|October 10, 2025
Unlocking insights from mother-infant linked data in pharmacoepidemiology: opportunities, challenges, and future directionsSigal Kaplan, Henok Tadesse Ayele, Dimitri Bennett, et al.Drug Development Research|March 5, 2020
Effect of age and renal impairment on the pharmacokinetics and safety of trimetazidine: An open-label multiple-dose studyNencho Nenchev, Jiri Skopek, Deepa Arora, et al.Schizophrenia Bulletin Open|January 26, 2026
Attitudes Driving Regional Differences in Long-Acting Injectable Antipsychotic Utilization for Schizophrenia among Healthcare Professionals, Patients, and Caregivers (ADVANCE): Results from a Multinational Survey StudyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.Annals of Internal Medicine|March 20, 2023
Assessing Heterogeneity of Treatment Effect in Real-World DataJodi B Segal, Ravi Varadhan, Rolf H H Groenwold, et al.Frontiers in Psychiatry|December 25, 2025
Experiences and perceptions of patients, caregivers, and healthcare professionals with long-acting injectable antipsychotics for the treatment of schizophrenia: qualitative results from the multinational ADVANCE studyKelli R Franzenburg, Rolf Hansen, Mark Suett, et al.Pageof 7